Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-024 in advanced neuroendocrine carcinoma
NCT06157827Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Dec 2023
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of opamtistomig in neuroendocrine carcinoma (NEC), sponsored by Leads Biolabs. Primary endpoints: Objective Response Rate, Dose-limiting toxicities at 3 weeks and 3 more. Started Dec 2023; status: recruiting.
02
Drugs
opamtistomig
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT06157827.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06157827.